Abstract

A Phase IV, prospective, observational cohort study examining patients changed from Atripla to Stribild for continued suppression of viral load, effect on CD-4 cells, quality of life and sleep using blood tests and standardized questionnaires. While continuing to control the virus to acceptable levels, CD 4 counts were noted to rise and patients experienced fewer CNS side effects. Sleep quality was also improved.